On August 24-25, 2024, the "7th Advanced Training Course for Non Clinical Safety Evaluation of Drugs" was held in Qingdao, Shandong Province. Liu Baofeng, General Manager of Shandong Xinbo Pharmaceutical Research Co., Ltd. (hereinafter referred to as "Shandong Xinbo"), brings a wonderful report on the theme of "Focus and Case Analysis of Traditional Chinese Medicine Safety Evaluation".

Liu Baofeng

General Manager of Shandong Xinbo Pharmaceutical Research Co., Ltd., Deputy Director of the Drug Safety Evaluation Research Center, and Executive Member of the Chinese Society of Traditional Chinese Medicine's Chinese Medicine Toxicology and Safety Research Branch. I have been engaged in drug safety evaluation work for 21 years. As the project leader, I have led and completed the safety evaluation of more than 120 Class 1 chemical drugs, more than 60 traditional Chinese medicine drugs, more than 300 generic drugs, and more than 130 vaccines and biomacromolecule drugs. I have accumulated rich experience in preclinical safety evaluation of drugs.

Review of Academic Reports

General Manager Liu Baofeng gave a detailed report on the toxicity overview of traditional Chinese medicine, the selection of safety evaluation test items, the focus of sample, the focus of experimental design, and the focus of result analysis.

Based on the years of research experience in the safety evaluation of traditional Chinese medicine at Shandong Xinbo An Evaluation Center, the non clinical research focus of traditional Chinese medicine varieties was introduced in a simple and understandable way through case studies, which received enthusiastic discussion from the students. After the meeting, General Manager Liu Baofeng had in-depth discussions with the students.

Participants of Shandong Xinbo Pharmaceutical Research Co., Ltd. took a group photo to commemorate the occasion